Metsera says Novo Nordisk’s new up to $10 billion bid for obesity drugmaker is ‘superior’ to revised Pfizer offer (2025-11-04)
The clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as companies like Pfizer race to break in.